Edgewise Therapeutics, Inc.

Fundamentals7.0
Price Action6.0
News Sentiment7.0
AI Rating
6.0

Key Drivers

  • Very high liquidity
  • Zero reported revenue
  • Large operating losses

AI
AI Summary

6.0

Edgewise is a classic binary-on-de-risk investment: the stock's premium valuation hinges on positive near‑term clinical readouts (especially the GRAND CANYON pivotal for sevasemten) that could justify current multiples, otherwise upcoming financing needs and potential dilutive raises will likely compress the valuation. Actionable focus: monitor GRAND CANYON readout quality/timing, quarterly burn cadence and announced financing or partnership terms—positive data or a non‑dilutive deal is the primary upside trigger; ambiguous/negative readouts or a down‑round are the primary downside triggers.

Sevasemten
FinancingRisk
CatalystWatch‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

7.0

Key Financial Insights:

  • Very high liquidity
  • Zero reported revenue
  • Large operating losses

EWTX is highly liquid and conservatively financed but currently unprofitable with zero revenue and large, persistent cash burn, creating a significant market premium to book despite negative earnings.

Liquidity
NoRevenue

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Range-bound action
  • Resistance rejection
  • Support cluster

Over the last month EWTX has traded range-bound, slipping ~0.8% to $29.06 with clear rejection near ~$31.00 resistance, consolidation around $29–$30, and support near $27.82–$28.00 amid elevated intra-range volatility.

consolidation
breakrisk
Support Level: $27.82–$28.00
Resistance Level: $31.00

Elevated ~3-point intra-range swing (peak ~$30.99 to trough $27.82) increasing execution risk

Sentiment & News

7.0

Key News Insights:

  • Pivotal Q4 readout
  • 3.5‑yr positive data
  • Growing investor interest

Edgewise is advancing toward multiple near‑term catalysts—CIRRUS‑HCM 12‑week and Phase 1 EDG‑15400 data in H1 2026 and a pivotal GRAND CANYON sevasemten readout in Q4 2026—backed by 3.5‑year stabilization data, heightened investor coverage and modest new‑hire option grants.

Sevasemten

These developments should lift investor sentiment and valuation ahead of binary readouts, though near‑term upside hinges on the upcoming clinical results